Cadrenal Therapeutics
CVKD | NASDAQ
$1.40
-$0.11 (-7.28%)
At close: Nov 16, 2026, 4:00 PM ET
$1.57
+$0.17 (+12.39%)
After-hours:
Nov 16, 2026, 7:42 PM ET
Cadrenal Therapeutics Company Profile
Company profile explainedCompany Profile
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.
Key Executives
| Name | Position |
|---|---|
| Quang X. Pham | Chairman & Chief Executive Officer |
| Jeffrey Cole | Chief Operating Officer |
| John Sharp | Interim CFO & Principal Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 13, 2026 | 4 | Filing |
| Oct 13, 2026 | 4 | Filing |
| Oct 13, 2026 | 4 | Filing |
| Oct 13, 2026 | 4 | Filing |
| Oct 13, 2026 | 4 | Filing |
| Oct 08, 2026 | S-8 | Filing |
| Oct 07, 2026 | 8-K | Current Report |
| Sep 29, 2026 | 8-K | Current Report |
| Sep 03, 2026 | S-8 | Filing |
| Aug 31, 2026 | 8-K | Current Report |
Cadrenal Therapeutics
| Country | United States |
| IPO Date | Jan 20, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Quang X. Pham |
Contact Details
822 A1A North Ponte Vedra,
Florida 32082 United States
Stock Details
| Ticker Symbol | CVKD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001937993 |
| CUSIP Number | 127636207 |
| ISIN Number | US1276362076 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove CVKD